Research library
Sources, with the status on the record.
Each row is a paper or a ClinicalTrials.gov entry checked on 21 November 2026. Titles are the authors’ or the registry’s words. Nalen Lab does not restate them as claims about these products. A registration is not a result.
Records checked 2026-11-21. Open registry rows in this view: 1. Selank has published papers and no verified intervention trial.
Loading filters…
TB-500
2012
Publication
Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential.
Esposito S et al. · Drug Testing and Analysis
PublishedSame compound as the catalogue listing
Analytical characterisation of the fragment sold as TB-500. It is not a clinical efficacy study.
View in the catalogueTB-500
1999
Publication
Thymosin beta4 accelerates wound healing.
Malinda KM et al. · Journal of Investigative Dermatology
PublishedRelated molecule — not the catalogue compound
This paper studies full-length thymosin β4, not the acetylated 17–23 fragment named TB-500 in the Nalen Lab catalogue.
View in the catalogueTB-500
2012
Publication
Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications.
Goldstein AL et al. · Expert Opinion on Biological Therapy
PublishedRelated molecule — not the catalogue compound
Review of full-length thymosin β4, not the TB-500 fragment.
View in the catalogueTB-500
2026
Registry
TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD
Phase 1/2 · ClinicalTrials.gov · NCT07487363 · Hudson Biotech
RecruitingSame compound as the catalogue listing
The record names the 17–23 fragment. Checked 21 November 2026. A registration is not a result.
View in the catalogueTB-500
2023
Registry
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
Phase 3 · ClinicalTrials.gov · NCT05555589 · ReGenTree, LLC
CompletedRelated molecule — not the catalogue compound
RGN-259 is an ophthalmic solution of thymosin β4 (Tβ4), not the TB-500 fragment. Status Completed when checked on 21 November 2026.
View in the catalogueTB-500
2011
Registry
Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye
Phase 2 · ClinicalTrials.gov · NCT01387347 · ReGenTree, LLC
CompletedRelated molecule — not the catalogue compound
Full-length thymosin β4 eye drops, not the TB-500 fragment.
View in the catalogue